Drugs / Rituximab and Hyaluronidase Human
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT03719131 | Jun 2019 → Sep 2022 overdue | cutaneous melanoma | Emory University | Active not recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Rituximab and Hyaluronidase Human | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03719131 ↗ |
| Route | Intravenous | “Given IV or SC” NCT03719131 ↗ |
| Route | Subcutaneous | “Given IV or SC” NCT03719131 ↗ |